BRAF and glioma: Because the BRAF fusion is expressed in 70% of PAs, we prospectively collected patients’ glioma samples to comprehensively characterize the unique immune biology of these tumors using NanoString profiling, scRNA-Seq, and sequential immunofluorescence (seqIF) multiplex staining (Figure 2A).